Journal article
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer
The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen.
Given the limited power of microarray signatures to predict therapeutic response in associative studies of small clinical trial cohorts, the use of functional genomic data combined with expression or sequence analysis of genes and microRNAs implicated in drug response in human tumours may provide a more robust method to guide adjuvant treatment strategies in breast cancer that are transferable across different expression platforms and patient cohorts.
| Language: | English |
|---|---|
| Publisher: | BioMed Central |
| Year: | 2008 |
| Pages: | 214 |
| ISSN: | 1465542x and 14655411 |
| Types: | Journal article |
| DOI: | 10.1186/bcr2159 |
Antineoplastic Agents Breast Cancer Breast Neoplasms Cell Line, Tumor Chemotherapy, Adjuvant Cytotoxins Drug Resistance, Neoplasm Drug Sensitivity Female Gene Expression Profiling Gene Expression Signature Humans Multicenter Studies as Topic Neoplasm Proteins Oligonucleotide Array Sequence Analysis PARP Inhibitor Patient Selection Prognosis RNA Interference RNA, Small Interfering Randomized Controlled Trials as Topic Reverse Transcriptase Polymerase Chain Reaction Trastuzumab Validation Studies as Topic
